A "huge breakthrough" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common form of advanced disease.
The drug, capivasertib (also known as Truqap), offers new hope for up to 3,000 women annually with hormone receptor (HR)-positive, HER2-negative breast cancer harbouring specific genetic mutations and exhibiting spread.